Cellecta, Inc., founded in 2006, is a prominent player in the Biotechnology and Health Care industries, headquartered in the United States. The company simplifies the complex process of gene functional analysis, living up to its slogan: "Gene Functional Analysis. Simplified."
Cellecta specializes in HT loss-of-function genetic screening services, which are crucial for the discovery and functional characterization of novel therapeutic targets. Their offerings include pooled lentiviral shRNA and CRISPR libraries, pooled library screening, analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs along with isogenic cell lines.
Despite its comprehensive service suite and extensive experience, Cellecta has not attracted any recent investments. This could present an opportunity for potential investors to engage with a mature yet innovation-driven company that supports pivotal advancements in genetic research.